Robert I. Blum, President and Chief Executive Officer of Cytokinetics Inc. (NASDAQ:CYTK), has executed a transaction involving the sale of 7,500 shares of the company’s common stock. The sale occurred on July 1, 2026, with the shares disposed of at a price of $84.92 per share. This activity resulted in total proceeds of approximately $636,900. The transaction was structured under a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged sales of company securities.
Following the execution of this sale, Mr. Blum’s direct holdings in Cytokinetics common stock stand at 377,830 shares. In addition to his direct ownership, Mr. Blum maintains indirect stakes in the company. These indirect holdings include 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and an equal amount of 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
The insider transaction takes place against a backdrop of significant movement in Cytokinetics’ stock price. The company’s shares were trading at $86.48 at the time of reporting, a level near their 52-week high of $88.31. Over the past year, the stock has delivered a substantial return of 148%. Despite this performance, some analysis indicates that the company may be overvalued at its current market price. Cytokinetics currently commands a market capitalization of $11.71 billion.
Concurrently, Cytokinetics is advancing its commercial footprint for its heart drug, Myqorzo. The company has launched Myqorzo in Germany, marking its first entry into the European market. This launch follows approval by the European Commission earlier this year. The expansion is part of a broader strategy to increase the drug’s availability for treating symptomatic obstructive hypertrophic cardiomyopathy in adults.
Market analysts have responded positively to recent developments. UBS upgraded Cytokinetics to a Buy rating from Neutral, citing strong launch momentum for Myqorzo. UBS increased its price target from $69 to $115. The firm projects peak revenues for Myqorzo to reach $5.7 billion, an increase from a previous estimate of $4 billion. Mizuho also raised its price target for Cytokinetics to $118, maintaining an Outperform rating. Mizuho highlighted the drug’s strong launch performance and positive trial results. RBC Capital reaffirmed its Outperform rating with a $119 price target, noting potential for a stock rebound following recent trial data releases.
Further reinforcing the clinical profile of its asset, Cytokinetics presented new data on Myqorzo at the European Society of Cardiology Heart Failure Congress. The presentation showcased analyses from several clinical trials, underscoring the company’s commitment to advancing treatments for obstructive hypertrophic cardiomyopathy.